Moderna, Inc. Hits New 52-Week High at $62.30 Amid Market Challenges

Moderna, Inc., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 62.30 on June 17, 2026. This achievement marks a notable rebound from its previous low of USD 22.29, reflecting a substantial increase in its stock price over the past year. Despite this recent high, Moderna's one-year performance shows a decline of 58.41%, contrasting sharply with the S&P 500's gain of 24.03% during the same period. The company's market capitalization stands at approximately USD 19,573 million, indicating its mid-cap status within the industry. Financial metrics reveal that Moderna is currently loss-making, with a negative return on equity of -32.62% and a debt-to-equity ratio of -0.60. The company does not offer a dividend, and its price-to-book ratio is 2.26. As Moderna continues to navigate the evolving landscape of the pharmaceutical industry, this recent price milestone underscores the stock's volatility and the broader market dynamics at play.